Piper Sandler analyst Jason Bednar lowered the firm’s price target on Steris to $215 from $235 and keeps an Overweight rating on the shares. The company’s fiscal Q3 results were disappointing versus expectations, with revenue and margins each missing across three of four segments, the analyst tells investors in a research note. The analyst wants to see better execution against guidance moving forward.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on STE:
- Steris sees FY23 adjusted EPS $8.00-$8.10, consensus $8.43
- Steris reports Q3 adjusted EPS $2.02, consensus $2.19
- STERIS Announces Financial Results for Fiscal 2023 Third Quarter
- STERIS Declares $0.47 per share Dividend
- STERIS to Host a Conference Call for Fiscal 2023 Third Quarter Financial Results on February 9, 2023